RFMN in Combination With 1927 nm Thulium Laser for Treating Photoaged Skin
Launched by UNIVERSITÄTSKLINIKUM HAMBURG-EPPENDORF · Sep 1, 2023
Trial Information
Current as of July 25, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a combined treatment using radiofrequency micro needling (RFMN) and a specific type of laser called thulium laser to improve the appearance of aging skin. The goal is to see how effective this treatment is for reducing wrinkles, improving skin firmness, and addressing pigmented spots on the face. Researchers will also look at how satisfied patients are with the results and ensure the treatment is safe.
To participate, you need to be at least 30 years old and have issues like wrinkles or skin sagging that could benefit from this treatment. It's important that you are in good health and can attend follow-up appointments. However, people with certain conditions, such as severe acne, recent cosmetic procedures, or those who are pregnant or breastfeeding, cannot join the study. If you decide to participate, you can expect to receive the combined treatment and will be monitored for results and any side effects, helping researchers understand how well this approach works for improving photoaged skin.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Men and women from the age of 30 years
- • good general condition, no relevant previous diseases
- • Presence of wrinkles, dermatochalasis on the face, pigment spots, which are an indication for RFMN and thulium laser or comparable methods
- • Cognitive ability and willingness to give consent (informed consent)
- • Be willing and able to attend follow-up visits
- Exclusion Criteria:
- • Age \< 30 years
- • Pregnancy or breastfeeding
- • Excessive subcutaneous fatty tissue under the cheeks
- • Significant scarring of the region to be treated
- • open wounds or lesions of the region to be treated
- • Severe or cystic facial acne
- • Metallic implants in the face or neck region
- • Mental illnesses (psychoses, body perception disorders)
- • Use of isotretinoin or other retinoids, psychotropic drugs, coumarins or heparins in the last 2 weeks
- • Fillers in the region to be treated \< 4 weeks prior and during the study period
- • Resurfacing (fractional, ablative, nonablative) of the region of interest \< 2 months prior and during the study period
- • Plastic aesthetic procedures or other surgical procedures \< 6 months prior and during the study period
- • Tendency to have excessive scarring
- • Lack of informed consent
About Universitätsklinikum Hamburg Eppendorf
Universitätsklinikum Hamburg-Eppendorf (UKE) is a leading academic medical center in Germany, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, UKE integrates state-of-the-art facilities with a multidisciplinary approach, fostering collaboration among top-tier researchers, clinicians, and healthcare professionals. The institution is dedicated to improving patient outcomes by conducting rigorous scientific investigations that address critical health challenges, ultimately contributing to the development of novel therapies and enhancing medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hamburg, , Germany
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported